Filing Flows › Comparisons › BCRX vs ALEC
Biocryst Pharmaceuticals vs Alector: BCRX and ALEC compared
Biocryst Pharmaceuticals is the larger company: $180M of revenue in its latest quarter (Q3 2026) against $163M for Alector (Q3 2026). Alector is growing faster (50× against +13% a year earlier). Alector is more profitable, with an operating margin of 76.0% against 29.6%.
Where the money goes: BCRX and ALEC
Biocryst Pharmaceuticals (BCRX) · Q3 2026
Biocryst Pharmaceuticals, Q3 2026: revenue $180M (+13% year over year), operating margin 29.6%, net earnings $37.9M, operating cash flow $33.0M. The chart follows the revenue to costs, profit and cash.
Alector (ALEC) · Q3 2026
Alector, Q3 2026: revenue $163M (50× year over year), operating margin 76.0%, net earnings $125M, operating cash flow −$24.2M. The chart follows the revenue to costs, profit and cash.
| Biocryst Pharmaceuticals (BCRX) | Alector (ALEC) | |
|---|---|---|
| Latest quarter | Q3 2026 | Q3 2026 |
| Revenue | $180M | $163M |
| Revenue growth, Y/Y | +13% | 50× |
| Operating margin | 29.6% | 76.0% |
| Net earnings | $37.9M | $125M |
| Net margin | 21.0% | 76.5% |
| Operating cash flow | $33.0M | −$24.2M |
| Free cash flow | $32.8M | — |
Where the revenue comes from
Biocryst Pharmaceuticals
- Product: $172M (96%)
- License and other revenues: $8.0M (4%)
Questions
Which is bigger, Biocryst Pharmaceuticals or Alector?
Biocryst Pharmaceuticals is the larger company: $180M of revenue in its latest quarter (Q3 2026) against $163M for Alector (Q3 2026).
Is Biocryst Pharmaceuticals or Alector growing faster?
Alector is growing faster (50× against +13% a year earlier).
Which is more profitable, Biocryst Pharmaceuticals or Alector?
Alector is more profitable, with an operating margin of 76.0% against 29.6%.
More: Biocryst Pharmaceuticals earnings · how Biocryst Pharmaceuticals makes money · Alector earnings · how Alector makes money
From the companies' latest 10-Q, 10-K or earnings release (10-Q filed Nov 4, 2026; 10-Q filed Nov 5, 2026). Fiscal quarters can end on different dates. Not investment advice.